Table 1

Rare coding variants detected in probands with paediatric cataract

Family IDPhenotypeGeneGenomic changeCoding changeProtein changegnomAD popmaxCADD/Polyphen2/SIFT/
PROVEAN
SegFirst publicationACMG-AMP
Pathogenic/Likely pathogenic variants
CRCH21CentralGJA3Chr13:20 717 252G>ANM_021954.4:c.176C>Tp.(Pro59Leu)027.7/PrD/D/DYesBennett et al37LP
CRCH90Dense nuclearGJA3Chr13:20 717 372G>ANM_021954.4:c.56C>Tp.(Thr19Met)027.3/PrD/D/DYesSanthiya et al38LP
CRCH29CRYAAChr21:44589243C>TNM_000394.4:c.34C>Tp.(Arg12Cys)028/PrD/D/DYesHansen et al24LP
CRCH38Central posterior cortical with dotsCOL4A1Chr13:110833673C>TNM_001845.6:c.2159G>Ap.(Gly720Asp)023.9/PrD/D/DYesSibon et al33LP
MIR184Chr15:79502181T>CNR_029705.1:n.52T>Cn/a016.87/-/-/-YesVUS
CSA168Lamellar/zonularHSF4Chr16:67 199 491A>GNM_001040667.3:c.190A>Gp.(Lys64Glu)029.4/PrD/D/DDe novo?Berry et al23LP
CRCH28Posterior subcapsularPITX3Chr10:103990272C>ANM_005029.4:c.908G>Tp.(Ter303LeuextTer100)018.39/-/-/-YesLP
EYA1Chr8:72 127 864G>ANM_000503.6:c.1460C>Tp.(Ser487Leu)0.00122.8/B/T/NNoB
CSA182Posterior suturalBFSP1Chr20:17 475 593delNM_001195.5:c.1124delp.(Glu375Glyfs
Ter2)
032/-/-/-YesLP
CRVEEH77Nuclear or dense totalGJA8Chr1:147380647C>TNM_005267.5:c.565C>Tp.(Pro189Ser)025.7/PrD/D/DYes*Hansen et al24
Fernández-Alcalde et al25
LP
Variants of uncertain significance with evidence towards pathogenicity
CRCH137LamellarGJA8Chr1:147 380 146G>ANM_005267.5:c.64G>Ap.(Gly22Ser)026.9/PrD/D/DYes*Wang et al27
Fernández-Alcalde et al25
Ye et al28
VUS
CTAS71Central nuclearGJA8Chr1:147380470_147380472delNM_005267.5:c.388_390delp.(Lys131del)014.76 /-/-/Nn/aVUS
CSA192GJA3Chr13:20 717 385G>TNM_021954.4:c.43C>Ap.(Gln15Lys)024.2/PsD/D/Nn/aVUS
CRVEEH79Blue dotLEMD2Chr6:33756893T>CNM_001348710.2:c.1A>Gp.(?)023.2/B/D/NYesVUS
CSA93Dense post central with lenticonusPRXChr19:40904522C>TNM_020956.2:c.386G>Ap.(Arg129His)018.86/PsD/T/NYesVUS
CTAS34Anterior polar & nuclearCRYBB1Chr22:27 008 054A>TNM_001887.4:c.281T>Ap.(Ile94Asn)025.6/PrD/D/DYesVUS
MIPChr12:56847410C>TNM_012064.4:c.490G>Ap.(Val164Ile)1.0×10–415.54/B/T/NRP?VUS
CQLD130BFSP2Chr3:133119192C>TNM_003571.4:c.265C>Tp.(Arg89Trp)1.0×10–423.2/PrD/T/DRP?VUS
CRCH4NuclearMIPChr12:56848060C>TNM_012064.4:c.338G>Ap.(Arg113Gln)029.1/PrD/D/DRP?VUS
Variants of uncertain significance that are unlikely to be causing disease
CSA158Lamellar or corticalCYP51A1Chr7:91761099C>TNM_000786.4:c.280G>Ap.(Ala94Thr)028.8/PrD/D/NYesVUS
WFS1Chr4:6302631C>TNM_001145853.1:c.1109C>Tp.(Ala370Val)025.9/PrD/T/NNoVUS
CRCH5Mid-periphery cortical dots, anterior polarLONP1Chr19:5 694 473G>ANM_001276480.1:c.1657C>Tp.(Pro553Ser)026.1/PrD/D/DNo †1/1VUS
CSA178LamellarIARS2Chr1:220 279 332G>CNM_018060.4:c.1166G>Cp.(Gly389Ala)026.8/PrD/D/DNoVUS
CQLD88FBN1Chr15:48 779 550G>ANM_000138.5:c.3422C>Tp.(Pro1141Leu)6.4×10–528/PrD/D/DRP?VUS
CSA100NuclearLSSChr21:47 647 553G>CNM_001001438.3:c.232C>Gp.(Leu78Val)6.5×10–516.77/B/T/NNoVUS
  • Rare coding variants identified in the probands and assessment of cosegregation in the family. Section 1; pathogenic variants, section 2; variants of uncertain significance and section 3; variants unlikely to be disease-causing. Genomic change reported using human reference genome hg19. ‘–’ indicates data not available, n/a indicates not applicable. gnomAD popmax minor allele frequency represents highest frequency observed in V.2.1.1 data release. Variant predicted functional effects using CADD version 1.639 40 with PHRED score given; Polyphen-241 ‘PrD’ probably damaging, ‘PsD’ possibly damaging, ‘B’ benign, SIFT42 ‘D’ damaging, ‘T’ tolerated, PROVEAN43 ‘D’ damaging, ‘N’ neutral, ‘–’ scoring unavailable. Seg; cosegregation in the family either Yes, No, de novo?, RP? if possible reduced penetrance, or ‘n/a’ singleton and not applicable. Variant interpretation based on the ACMG-AMP guidelines.15

  • *Reported alternate amino acid change at same location.

  • †1/1 homozygous observation of variant in proband.

  • ACMG, American College of Medical Genetics and Genomics; B, benign; LP, likely pathogenic; n/a, not available; P, pathogenic; VUS, variant of uncertain significance.